Israeli - Kiebrania - Ministry of Health

abbott medical laboratories ltd, israel - ferrous sulfate; folic acid - טבליה - folic acid 0.35 mg; ferrous sulfate 325.0 mg - folic acid, combinations - folic acid, combinations - for the treatment and prevention of iron deficiency anaemia and for the prevention of folic acid deficiency in non-pregnant adults.

Israeli - Kiebrania - Ministry of Health

rekah pharmaceutical industry ltd, israel - benzocaine; bismuth subgallate; zinc oxide - פתילות - bismuth subgallate 180 mg; zinc oxide 120 mg; benzocaine 15 mg - bismuth preparations, combinations - bismuth preparations, combinations - for the relief of hemorrhoids.

Israeli - Kiebrania - Ministry of Health

meditrend marketing (2004) ltd, israel - benzoxonium chloride; chlorhexidine as gluconate; vitamin a palmitate - משחה - vitamin a palmitate 0.2 %w/w; benzoxonium chloride 0.1 %w/w; chlorhexidine as gluconate 0.5 %w/w - chlorhexidine, combinations - chlorhexidine, combinations - disinfection of minor superficial wounds, minor burns (first degree).

Israeli - Kiebrania - Ministry of Health

bayer israel ltd - testosterone undecanoate - תמיסה להזרקה - testosterone undecanoate 250 mg/ml - testosterone - testosterone - testosterone replacement therpay in primary and secondary male hypogonadism.

Israeli - Kiebrania - Ministry of Health

abbott medical laboratories ltd, israel - clarithromycin - גרנולות להמסה - clarithromycin 125 mg / 5 ml - clarithromycin - clarithromycin - bronchitis, pharyngitis, tonsilitis pneumonia skin infections due to susceptible microorganisms. treatment of mycobacterium avium complex in patients with aids. treatment of otitis media.

Israeli - Kiebrania - Ministry of Health

astra zeneca (israel) ltd - fulvestrant - תמיסה להזרקה - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - faslodex is indicated for the treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant antioestrogen therapy or disease progression on therapy with an antioestrogen.

Israeli - Kiebrania - Ministry of Health

astra zeneca (israel) ltd - fulvestrant - תמיסה להזרקה - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - faslodex is indicated for the treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant antioestrogen therapy or disease progression on therapy with an antioestrogen.06/06/2010 בקשה לשינוי משטר מינון the recommended dose is 500 mg at intervals of one month, with an additional 500 mg dose given two weeks after the initial dose.

Israeli - Kiebrania - Ministry of Health

astrazeneca (israel) ltd - fulvestrant - תמיסה להזרקה - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - faslodex is indicated for the treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant antioestrogen therapy or disease progression on therapy with an antioestrogen.

Israeli - Kiebrania - Ministry of Health

abbvie biopharmaceuticals ltd, israel - ciclosporin - תחליב לעין - ciclosporin 0.05 % - cyclosporin - cyclosporin - to increase tear production in patients whose tear production is presumed to be supressed due to ocular inflammation associated with keratoconjunctivitis sicca. increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

Israeli - Kiebrania - Ministry of Health

rafa laboratories ltd - nimesulide - קפליות - nimesulide 100 mg - nimesulide - nimesulide - acute pain.primary dysmenorrhea.